Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Cardiotoxicity|Heart Failure|Breast Cancer|Anthracycline Induced Cardiomyopathy|Biomarkers|Echocardiography
Sponsor: Stony Brook University
Collaborators: Gilead Sciences